Commentary on Composite cognitive and functional measures for early stage Alzheimer's disease trials.
作者信息
Rentz Dorene M, Papp Kathryn V
机构信息
Harvard Medical School Boston Massachusetts.
出版信息
Alzheimers Dement (Amst). 2020 May 15;12(1):e12012. doi: 10.1002/dad2.12012. eCollection 2020.
Abstract
摘要
相似文献
1
Commentary on Composite cognitive and functional measures for early stage Alzheimer's disease trials.早期阿尔茨海默病试验中综合认知和功能测量的评论
Alzheimers Dement (Amst). 2020 May 15;12(1):e12012. doi: 10.1002/dad2.12012. eCollection 2020.
2
Commentary: Composite cognitive and functional measures for early stage Alzheimer's disease trials.评论：用于早期阿尔茨海默病试验的综合认知和功能测量方法
Alzheimers Dement (Amst). 2020 May 15;12(1):e12009. doi: 10.1002/dad2.12009. eCollection 2020.
3
Development of a Cognitive Composite for Preclinical Alzheimer's Disease in Korean Older Adults.开发一种针对韩国老年人群体的临床前阿尔茨海默病认知综合测试。
J Alzheimers Dis. 2023;96(2):633-641. doi: 10.3233/JAD-230263.
4
The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.阿尔茨海默病预防计划综合认知测试分数：早老素1 E280A突变携带者中用于评估临床前阿尔茨海默病治疗的样本量估计
J Clin Psychiatry. 2014 Jun;75(6):652-60. doi: 10.4088/JCP.13m08927.
5
Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.临床前阿尔茨海默病认知综合指标（PACC）对临床前阿尔茨海默病淀粉样β负荷的敏感性。
J Clin Exp Neuropsychol. 2019 Aug;41(6):591-600. doi: 10.1080/13803395.2019.1593949. Epub 2019 Mar 29.
6
Souvenaid for Alzheimer's disease.用于治疗阿尔茨海默病的苏威艾迪。
Cochrane Database Syst Rev. 2020 Dec 15;12(12):CD011679. doi: 10.1002/14651858.CD011679.pub2.
7
The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease.阿尔茨海默病预防计划综合认知测试：一种用于跟踪临床前阿尔茨海默病认知能力下降的实用方法。
Alzheimers Res Ther. 2020 May 27;12(1):66. doi: 10.1186/s13195-020-00633-2.
8
Sex-specific composite scales for longitudinal studies of incipient Alzheimer's disease.用于早期阿尔茨海默病纵向研究的性别特异性综合量表。
Alzheimers Dement (N Y). 2019 Oct 3;5:508-514. doi: 10.1016/j.trci.2019.07.003. eCollection 2019.
9
Response to Schneider and Goldberg "Composite cognitive and functional measures for early stage Alzheimer's disease trials".对施耐德和戈德堡《早期阿尔茨海默病试验的综合认知和功能测量》的回应
Alzheimers Dement (Amst). 2020 May 15;12(1):e12015. doi: 10.1002/dad2.12015. eCollection 2020.
10
Response to peer commentaries: Composite cognitive and functional measures for early stage Alzheimer's disease trials.对同行评论的回应：用于早期阿尔茨海默病试验的综合认知和功能测量指标
Alzheimers Dement (Amst). 2020 May 15;12(1):e12024. doi: 10.1002/dad2.12024. eCollection 2020.
引用本文的文献
1
Cognitive decline across five cognitive batteries: Sample size implications for clinical trials.五项认知测试中的认知衰退：对临床试验样本量的影响
Alzheimers Dement (N Y). 2025 Jul 16;11(3):e70137. doi: 10.1002/trc2.70137. eCollection 2025 Jul-Sep.
2
Face Name Associative Memory Exam and biomarker status in the ARMADA study: Advancing reliable measurement in Alzheimer's disease and cognitive aging.ARMADA研究中的面孔-名字联想记忆测试与生物标志物状态：推进阿尔茨海默病和认知衰老的可靠测量
Alzheimers Dement (Amst). 2023 Sep 7;15(3):e12473. doi: 10.1002/dad2.12473. eCollection 2023 Jul-Sep.
3
Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease.为何临床试验与结局测量同等重要：阿尔茨海默病临床试验中认知结局测量选择和使用的框架。
Alzheimers Dement. 2023 Feb;19(2):708-720. doi: 10.1002/alz.12773. Epub 2022 Sep 10.
本文引用的文献
1
Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD.临床前期 AD 纵向测试中轻微认知衰退的临床意义。
Alzheimers Dement. 2020 Mar;16(3):552-560. doi: 10.1016/j.jalz.2019.09.074. Epub 2020 Jan 4.
2
Determining clinically meaningful decline in preclinical Alzheimer disease.在临床前阿尔茨海默病中确定有临床意义的下降。
Neurology. 2019 Jul 23;93(4):e322-e333. doi: 10.1212/WNL.0000000000007831. Epub 2019 Jul 9.
3
Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts.性别、淀粉样蛋白、载脂蛋白 E ε4 与临床前阿尔茨海默病认知衰退的风险：三个特征明确队列的研究结果。
Alzheimers Dement. 2018 Sep;14(9):1193-1203. doi: 10.1016/j.jalz.2018.04.010. Epub 2018 May 24.
4
Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5.通过语义处理优化临床前阿尔茨海默病认知综合指标：PACC5
Alzheimers Dement (N Y). 2017 Nov 10;3(4):668-677. doi: 10.1016/j.trci.2017.10.004. eCollection 2017 Nov.
5
A Novel Eigenvector-based Method to Detect Mild Alzheimer's Disease Using Event-Related Potentials.一种基于特征向量的新型方法，利用事件相关电位检测轻度阿尔茨海默病。
J Prev Alzheimers Dis. 2016;3(2):101-104. doi: 10.14283/jpad.2016.79.
6
Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β.淀粉样β升高的临床正常老年人中临床前阿尔茨海默病认知综合指标的早期和晚期变化
Alzheimers Dement. 2017 Sep;13(9):1004-1012. doi: 10.1016/j.jalz.2017.01.018. Epub 2017 Feb 28.
7
Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis.认知正常的高淀粉样蛋白-β老年成年人的认知障碍与衰退：一项荟萃分析。
Alzheimers Dement (Amst). 2016 Oct 18;6:108-121. doi: 10.1016/j.dadm.2016.09.002. eCollection 2017.
8
Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer's disease.贝叶斯模型揭示了阿尔茨海默病中具有可分离认知轨迹的潜在萎缩因素。
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6535-E6544. doi: 10.1073/pnas.1611073113. Epub 2016 Oct 4.
9
Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community.社区认知正常人群中淀粉样蛋白水平升高与认知及生物标志物的关联
JAMA Neurol. 2016 Jan;73(1):85-92. doi: 10.1001/jamaneurol.2015.3098.
10
The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.临床前阿尔茨海默病认知综合评分：测量与淀粉样蛋白相关的衰退。
JAMA Neurol. 2014 Aug;71(8):961-70. doi: 10.1001/jamaneurol.2014.803.
Zotero 插件